pubmed-article:11958999 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11958999 | lifeskim:mentions | umls-concept:C0003308 | lld:lifeskim |
pubmed-article:11958999 | lifeskim:mentions | umls-concept:C0030020 | lld:lifeskim |
pubmed-article:11958999 | lifeskim:mentions | umls-concept:C0762202 | lld:lifeskim |
pubmed-article:11958999 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
pubmed-article:11958999 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:11958999 | pubmed:dateCreated | 2002-4-17 | lld:pubmed |
pubmed-article:11958999 | pubmed:abstractText | Oxime derivatives of the sordarin aglycone have been identified as potent antifungal agents. The in vitro spectrum of activity includes coverage against Candida albicans and Candida glabrata with MICs as low as 0.06 microg/mL. The antifungal activity was established to be exquisitely sensitive to the spatial orientation of the lipophilic side chains. | lld:pubmed |
pubmed-article:11958999 | pubmed:language | eng | lld:pubmed |
pubmed-article:11958999 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11958999 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11958999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11958999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11958999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11958999 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11958999 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11958999 | pubmed:month | Mar | lld:pubmed |
pubmed-article:11958999 | pubmed:issn | 0960-894X | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:BarrettJohn... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:Serrano-WuMic... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:St ... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:MazzuccoCharl... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:StickleTerry... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:VyasDolatrai... | lld:pubmed |
pubmed-article:11958999 | pubmed:author | pubmed-author:Balasubramani... | lld:pubmed |
pubmed-article:11958999 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11958999 | pubmed:day | 25 | lld:pubmed |
pubmed-article:11958999 | pubmed:volume | 12 | lld:pubmed |
pubmed-article:11958999 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11958999 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11958999 | pubmed:pagination | 943-6 | lld:pubmed |
pubmed-article:11958999 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:meshHeading | pubmed-meshheading:11958999... | lld:pubmed |
pubmed-article:11958999 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:11958999 | pubmed:articleTitle | Oxime derivatives of sordaricin as potent antifungal agents. | lld:pubmed |
pubmed-article:11958999 | pubmed:affiliation | Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA. michael.serrano-wu@bms.com | lld:pubmed |
pubmed-article:11958999 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11958999 | lld:chembl |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11958999 | lld:pubmed |